GT Biopharma (GTBP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on GT Biopharma (GTBP) is Neutral.

The composite score behind that read is -0.08, weighing +0.23 of bullish evidence against -0.32 bearish.

GT Biopharma last closed at $6.68, +12.08% on the session.

Against the IVW growth benchmark the position is +11.28% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

16 graded predictions for GTBP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks GT Biopharma in the 99th percentile on valuation and the 4th percentile on return on equity, where 100 is best.

GT Biopharma is classified under Health Care / Biotechnology, with a market capitalisation of $10.75M.

StockMap tracks GT Biopharma as the 357th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite GT Biopharma ranks 197th of 381 in the group, against a group median of -0.08.